Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 3
2004 3
2005 2
2006 1
2007 2
2008 6
2009 7
2010 1
2011 6
2012 5
2013 3
2014 7
2015 14
2016 4
2017 5
2018 7
2019 8
2020 9
2021 10
2022 7
2023 14
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

117 results

Results by year

Filters applied: . Clear all
Page 1
Designing a combined liothyronine (LT3), L- thyroxine (LT4) trial in symptomatic hypothyroid subjects on LT4 - the importance of patient selection, choice of LT3 and trial design.
Premawardhana LD, Taylor PN, Okosieme OE, Adlan MA, Obuobie EK, Dayan CM. Premawardhana LD, et al. Front Endocrinol (Lausanne). 2023 Nov 16;14:1282608. doi: 10.3389/fendo.2023.1282608. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 38034018 Free PMC article. Review.
C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis.
Taylor PN, Collins KS, Lam A, Karpen SR, Greeno B, Walker F, Lozano A, Atabakhsh E, Ahmed ST, Marinac M, Latres E, Senior PA, Rigby M, Gottlieb PA, Dayan CM; Trial Outcome Markers Initiative collaboration. Taylor PN, et al. Among authors: dayan cm. Lancet Diabetes Endocrinol. 2023 Dec;11(12):915-925. doi: 10.1016/S2213-8587(23)00267-X. Epub 2023 Nov 3. Lancet Diabetes Endocrinol. 2023. PMID: 37931637 Free article.
Single-cell RNAseq identifies clonally expanded antigen-specific T-cells following intradermal injection of gold nanoparticles loaded with diabetes autoantigen in humans.
Hanna SJ, Thayer TC, Robinson EJS, Vinh NN, Williams N, Landry LG, Andrews R, Siah QZ, Leete P, Wyatt R, McAteer MA, Nakayama M, Wong FS, Yang JHM, Tree TIM, Ludvigsson J, Dayan CM, Tatovic D. Hanna SJ, et al. Among authors: dayan cm. Front Immunol. 2023 Oct 16;14:1276255. doi: 10.3389/fimmu.2023.1276255. eCollection 2023. Front Immunol. 2023. PMID: 37908349 Free PMC article.
Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes.
Ramos EL, Dayan CM, Chatenoud L, Sumnik Z, Simmons KM, Szypowska A, Gitelman SE, Knecht LA, Niemoeller E, Tian W, Herold KC; PROTECT Study Investigators. Ramos EL, et al. Among authors: dayan cm. N Engl J Med. 2023 Dec 7;389(23):2151-2161. doi: 10.1056/NEJMoa2308743. Epub 2023 Oct 18. N Engl J Med. 2023. PMID: 37861217 Clinical Trial.
117 results